Early-stage Oncology Thetis is a clinical-stage biotech focused on TP-317, a first-in-class oral Resolvin E1 (RvE1) targeting BLT1 for inflammatory bowel disease and solid tumors, presenting a clear entry point for partnerships with pharma companies seeking innovative IBD and cancer therapies.

Strategic Partnerships Recent board and advisory appointments, plus notable funding from Helmsley Charitable Trust, indicate a strategy oriented toward collaboration and guidance, making Thetis a strong candidate for co-development, licensing, or sponsored research deals.

Clinical Progress Active movement toward Phase 1b in ulcerative colitis with data presentations at IBD Innovate and ECCO 2025 demonstrate near-term milestones that can align with potential CROs, contract manufacturing, and regulatory consulting opportunities.

Targeted Therapeutics By addressing BLT1-mediated immune pathways in IBD and cancer, Thetis offers a differentiated mechanism among Imaging/Diagnostics and Immuno-Oncology portfolios, enabling strategic outreach to companies seeking novel immunomodulatory assets.

Funding Readiness With revenue in the low millions and secured program-related investments, Thetis shows financial momentum and readiness for co-funding arrangements, essential for discussions on early-stage clinical development funding or grant-aligned collaborations.